Orphan designation: Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt (cabozantinib) Treatment of medullary thyroid carcinoma, 06/02/2009 Positive

Orphan designation: Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt (cabozantinib) Treatment of medullary thyroid carcinoma, 06/02/2009 Positive

Metadata
Provider: 
European Medicines AgencyEuropean Medicines Agency
URL: 
https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-610https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-08-610
Retrieved on: 
Mercredi, avril 3, 2024
Information
Tags: 
Community, Eurostat, Civil service commission, Thyroid cancer, Diagnosis, Metabolism, Diarrhea, Enzyme, Hormone, Growth, Thyroid hormones, Prevalence, Cell, Calcitonin, Disease, Patient, Malignancy, Committee, Knowledge, Tissue, Seriousness, Doxorubicin, Boulogne-Billancourt, Regulation, Cancer, EMA, IRIS, Thyroid neoplasm, Cabozantinib, Protein, Medullary thyroid cancer, Thyroid, European, COMP, Iodine, European Commission, Safety, Blood, Marketing, Human, Pharmaceutical industry
Geotags: 
EUROPEAN UNION, RARE, EC, SWEDEN, ICELAND, EU, FRANCE, NORWAY, UNITED KINGDOM, LIECHTENSTEIN
Résumé
Key Points: 


Orphan designation: Cyclopropane-1,1-dicarboxylic acid [4-(6,7-dimethoxy-quinolin-4-yloxy)-phenyl]-amide (4-fluoro-phenyl)-amide, (L)-malate salt (cabozantinib) Treatment of medullary thyroid carcinoma, 06/02/2009 Positive

Copyright: 
2024 European Medicines Agency. All Rights Reserved.